Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients

Anti-VEGF treatment of patients with diabetic macular edema

The aim of this thesis was to describe and evaluate visual acuity, macular edema and patientreported outcomes (PRO) following anti-VEGF treatment of diabetic macular edema (DME) patients in a real-world setting. Using a longitudinal study design, a cohort of DME patients was followed from baseline to 1 year after treatment start. Data were collected from two eye clinics at two county hospitals....

ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema

Anti-VEGF in treatment of diabetic macular edema.

Diabetic macular edema is the leading cause of moderate visual deterioration in patients with diabetic retinopathy. Ranibizumab) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy and safety of anti-VEGF treatment in reduction of central retinal thickness (CRT) and improvement in visual acuity...

Role of Anti-VEGF in Diabetic Macular Edema

A recent study has shown that RPE cells at the margins of laser burns modulate various cytokines via photoreceptors [8]. With the approval of two anti-VEGF agents by the FDA in recent years, the indication of focal/grid laser is now limited to patients with non-center involving DME. A recent DRCR study examined whether prompt laser treatment strategy along with anti-VEGF therapy was better in a...

Anti-VEGF for the Management of Diabetic Macular Edema

Diabetic retinopathy (DR) is an important cause of vision loss around the world, being the leading cause in the population between 20 and 60 years old. Among patients with DR, diabetic macular edema (DME) is the most frequent cause of vision impairment and represents a significant public health issue. Macular photocoagulation has been the standard treatment for this condition reducing the risk ...